A Blood Protein Signature Stratifies Clinical Response to csDMARD Therapy in Pediatric Uveitis

PURPOSE: To identify a serum biomarker signature that can help predict response to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in pediatric noninfectious uveitis. METHODS: In this case-control cohort study, we performed a 368-plex proteomic analysis of serum samples...

Descripción completa

Detalles Bibliográficos
Autores principales: Wennink, Roos A. W., Kalinina Ayuso, Viera, Tao, Weiyang, Delemarre, Eveline M., de Boer, Joke H., Kuiper, Jonas J. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819312/
https://www.ncbi.nlm.nih.gov/pubmed/35103800
http://dx.doi.org/10.1167/tvst.11.2.4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819312/
https://www.ncbi.nlm.nih.gov/pubmed/35103800
http://dx.doi.org/10.1167/tvst.11.2.4

Ejemplares similares